Emerging Variant Preprints (Hot Topics)

THIS MANUSCRIPT ARGUES THAT VARIANTS ARE MORE LIKELY TO EMERGE FROM UNVACCINATED POPULATIONS

IF CLAIMS ARE VERIFIED, THIS STUDY SHOWS THAT CURRENT VACCINES ARE NOT SUBSTANTIALLY AFFECTE BY THE MUTATIONS FOUND IN COMMON SARS-CoV-2 VARIANTS.

THIS DATA WILL BE HELPFUL IN DIRECTING WET BENCH GAIN-OF-FUNCTION STUDIES AND OFFERS A SHORT LIST OF VARIANTS TO TRACK IN COMING MONTHS

THIS MANUSCRIPT ARGUES THAT SERUM OF SPUTNIK-VACCINATED PEOPLE IS ABLE TO NEUTRALIZE PROMINENT SPIKE VARIANTS EXCEPT B.1.351

THIS MANUSCRIPT FINDS THAT THE ONLY DIFFERENCE IN VIRAL ENTRY BETWEEN THE B.1.1.7 VARIANT COMPARED TO B.1 IS THE SPEED AT WHICH IT ENTERS CELLS

THIS PREPRINT OFFERS A METHODOLOGY FOR FUNCTIONAL TESTING AND IDENTIFICATION OF RECOMBINANT VARIANTS

Reviewers: Art Reingold (UC Berkeley) | 📗📗📗📗◻️ • Konstantin Chumakov (U.S. Food and Drug Administration) | 📒📒📒◻️◻️ • Shivakumar Narayanan, Shyam Kottilil, Joel V. Chua (University of Maryland School of Medicine) | 📒📒📒◻️◻️

THIS PREPRINT DISCUSSES THE NEW VARIANT, B.1.617, THAT HAS BEEN SPREADING IN INDIA.

THIS PREPRINT INVESTIGATES CONTRIBUTIONS OF L452R AND Y453F TO IMMUNE EVASION.

THIS PREPRINT DISCUSSES THE STRUCTURE ANALYSIS OF VARIANTS OF CONCERN THAT DEMONSTRATE THE RBD MUTATIONS L452R, E484Q, AND Pb81R RESULT IN BETTER TRANSMISSIBILITY AND MAY AFFECT NEUTRALIZATION POTENTIAL.

ThIS PREPRINT DISCUSSES A PSEUDOVIRUS MADE WITH MULTI-MUTANT SPIKE VARIANTS FROM INDIA, AND WITH THE INDIVIDUAL SINGLE POINT MUTANTS, TESTED FOR NEUTRALIZATION VS. CONVALESCENT PATIENT SERA, VACCINE-ELICITED, AND REGENERON MONOCLONAL ANTIBODIES.

A PSEUDOVIRUS WITH MULTI-MUTANT SPIKE VARIANTS FROM INDIA, AND WITH THE INDIVIDUAL SINGLE POINT MUTANTS, TESTED FOR NEUTRALIZATION VS. CONVALESCENT PATIENT SERA, VACCINE-ELICITED, AND REGENERON MONOCLONAL ANTIBODIES.

THIS PREPRINT, UNLIKE OTHER, USES REPLICANT COMPETENT VIRUS, TESTS ALL 3 POTENTIAL AVENUES OF NEUTRALIZATION EVASION, AND COMPARES TO B.1.1.7 as well as B.1.351, and D. 614G.

THIS PREPRINT IS ONE OF THE FIRST STUDIES DESCRIBING GAIN-OF-FUNCTION PROPERTIES FOR MUTATIONS DEFINING THE LAMDA VARIANT AND INVESTIGATE THE NEUTRALIZING ANTIBODIES ELICITED BY CORONAVAC ARE LESS EFFECTIVE AGAINST THIS VARIANT.

THIS PREPRINT PROVIDES A COHORT STUDY COMPARING CLINICAL PROFILES AND OUTCOMES OF PATIENTS UNVACCINATED WITH VIRAL VECTOR AND INACTIVATED VIRUS.